Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05536102 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 9, 2023 (before its estimated September 30, 2023 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
This is a signle-arm, multi-center, open-lable, phase II study. The objective is to evaluate the effectiveness and safety of tislelizumab + oxaliplatin + capecitabine + PLD in the neoadjuvant treatment of resectable gastric adenocarcinoma.
Trial Details
NCT Number NCT05536102
Lead Sponsor Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions
(from sponsor)		 Gastric Cancer
Related terms Stomach Neoplasms
Enrollment 38 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov